International Symposium on
VIRUSES IN
CHRONIC FATIGUE SYNDROME
& POST-VIRAL FATIGUE

June 22 & 23, 2008
Baltimore, Maryland, USA

A satellite meeting of the
6th International Conference on HHV-6 & 7

HHV-6 Foundation  IACFS/ME
Dear Friends,

It gives me great pleasure to invite you to the inaugural Viruses In CFS satellite conference, which will follow immediately after the end of the 6th International Conference on HHV-6 & 7 on June 22nd through Monday, June 23rd.

There is increasing evidence of an infectious etiology in a subset of CFS patients, most often with viral agents. The sudden onset of CFS in some patients with an “infectious-like” illness, the nature of some of the symptoms, the state of chronic immune activation, and prospective epidemiologic studies demonstrating incident cases of CFS developing following several well-characterized and documented infectious illnesses have made plausible the possibility that the illness can be triggered and perpetuated by an infectious agent, at least in some patients with CFS.

For this reason, we are sponsoring this special satellite conference reviewing current information on the role of viral infectious agents in chronic fatigue syndrome.

This satellite conference would not have been possible if the HHV-6 Foundation had not initiated the suggestion. I would also like to thank Dharam Ablashi and Kristin Loomis for their expertise and advice in organizing this program, as well as the IACFS, the HHV-6 Foundation Scientific Advisory Board and staff, and the generous conference sponsors for their support.

Sincerely,
Anthony Komaroff
Symposium Co-Chair

SPONSORS OF THE SYMPOSIUM

HHV-6 FOUNDATION

ABOUT THE HHV-6 FOUNDATION
The HHV-6 Foundation is a non-profit entity formed in 2004 to encourage scientific exchange among scientists and to provide pilot grants for promising scientific and clinical research. An important mission of the Foundation is to disseminate new knowledge about this virus. The Foundation helps to research the disease associations that have been suggested for HHV-6. The Foundation is proud to organize and sponsor this conference and to support the dedicated virologists and clinicians who have worked so hard to bring clarity to the nature of viruses and their role in chronic fatigue syndrome.

Kristin Loomis, President & Executive Director
Dharam Ablashi, VP & Scientific Director
Courtney Hischier, VP
Jill Chase, Project Manager
Mona Eliassen, Chairman, Board of Directors

IACFS/ME

ABOUT THE IACFS
The mission of the IACFS/ME, a non-profit organization, is to promote, stimulate and coordinate the exchange of ideas related to CFS, ME, and fibromyalgia (FM) research, patient care and treatment. In addition, the IACFS/ME periodically reviews the current research and treatment literature and media reports for the benefit of scientists, clinicians and patients. The IACFS/ME also conducts and/or participates in local, national, and international scientific conferences in order to promote and evaluate new research and to encourage future research ventures and cooperative activities to advance scientific and clinical knowledge of these illnesses.

Nancy Klimas, MD, President
Birgitta Evengard, MD, PhD, Vice-President
Leonard Jason, PhD, Vice-President
Lucinda Bateman, MD, Secretary
Fred Friedberg, PhD, Treasurer
International Symposium on
VIRUSES IN CHRONIC FATIGUE SYNDROME & POST-VIRAL FATIGUE
JUNE 22 & 23, 2008

TARGET AUDIENCE:
Clinicians and scientists who study the role of viruses in chronic fatigue, post-infective fatigue, and CNS dysfunction.
The satellite symposium on Viral Infections in CFS provides you with opportunities to network with the participants and speakers to discuss the latest advances and issues on the molecular biology and pathogenesis of these viruses, and to share the latest news and views on diagnosis, antiviral therapy, and prophylaxis of these infections.

SATELLITE CONFERENCE TOPICS:
• Clinician forum on antiviral therapies
• HHV-6 in CFS
• Other Viruses in CFS
• Borna virus in CFS
• EBV in CFS
• Parvovirus B-19 in CFS
• Retrovirus K-18 activation
• Enterovirus
• Post viral fatigue

CONFERENCE CO-CHAIRS:
• Anthony Komaroff (USA)
• Andrew Lloyd (AUSTRALIA)

PROGRAM COMMITTEES:
• Dharam Ablashi (USA)
• John Chia (USA)
• Jonhan Kerr (UK)
• Anthony Komaroff (USA)
• Andrew Lloyd (Australia)
• Jose G. Montoya (USA)

PRIMARY SPONSORS:
• The HHV-6 Foundation
• IACFS/ME

CO-SPONSORS:
• THE CFIDS Association
• Whittemore Peterson Institute
• Epiphany Biosciences
• Angel Donors
## Speaker Topics

### HHV-6 & CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Komaroff MD</td>
<td>Overview on HHV-6 &amp; CFS</td>
</tr>
<tr>
<td>Kazuhiro Kondo MD, PhD</td>
<td>Identification of novel HHV-6 neurovirulent latent protein that causes mood disorders in CFS, psychosis and HHV-6 encephalopathy</td>
</tr>
<tr>
<td>Jose G. Montoya MD</td>
<td>Antiviral treatment of CFS patients with elevated antibodies to HHV-6 &amp; EBV</td>
</tr>
</tbody>
</table>

### Chronic EBV and CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbara Savoldo MD</td>
<td>Chronic EBV, fatigue and immunotherapy by cytotoxic T-cell lymphocyte infusion</td>
</tr>
<tr>
<td>Marshall Williams PhD</td>
<td>EBV DUTPase in CFS and sickness behavior</td>
</tr>
<tr>
<td>Brigitte Huber PhD</td>
<td>EBV and interferon activation of retrovirus K-18 in CFS</td>
</tr>
</tbody>
</table>

### Enterovirus and CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nora Chapman PhD</td>
<td>Overview of enterovirus infections and diagnostic testing</td>
</tr>
<tr>
<td>John Chia MD</td>
<td>Enterovirus infections in CFS</td>
</tr>
</tbody>
</table>

### Parvovirus and CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mariko Seishima MD</td>
<td>Elevated Parvovirus antibodies and complement in CFS</td>
</tr>
</tbody>
</table>

### Borna Virus and CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liv Bode PhD</td>
<td>Human Borna virus infections: a possible role in chronic fatigue syndrome?</td>
</tr>
<tr>
<td>Keizo Tomonaga DVM, PhD</td>
<td>Borna Virus antibodies in CFS patients vs. controls</td>
</tr>
</tbody>
</table>

### Immunological Markers and Infection in CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nancy Klimas MD</td>
<td>Immune markers in viral illness and CFS</td>
</tr>
</tbody>
</table>

### Post-viral Fatigue: Prospective Studies

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter White MD</td>
<td>Overview on Post-viral Fatigue</td>
</tr>
<tr>
<td>Andrew Lloyd MD</td>
<td>Post-viral fatigue after acute infections</td>
</tr>
<tr>
<td>Ute Vollmer-Conna BSc PhD UNSW</td>
<td>Cytokines in Post-viral fatigue</td>
</tr>
</tbody>
</table>

### Microarray Studies

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonthan Kerr MD, PhD</td>
<td>Gene expression subtypes in patients with CFS and ME</td>
</tr>
<tr>
<td>Suzanne Vernon PhD</td>
<td>Host genetics and viral infection</td>
</tr>
</tbody>
</table>

### Twin Studies on Viruses in CFS

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birgitta Evengard MD, PhD</td>
<td>Viral markers in Swedish twins discordant for CFS</td>
</tr>
</tbody>
</table>

### Clinician Forum: Treating CFS Patients with Antivirals

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Peterson MD</td>
<td>Antiviral treatment of patients with HHV-6, EBV &amp; Enterovirus: Case reports</td>
</tr>
<tr>
<td>Kenny De Meirleir MD, Ph.D</td>
<td>RNaseL activity: correlation to viral infection in CFS and viral infections</td>
</tr>
<tr>
<td>Marin Lerner, MD</td>
<td>EBV &amp; CMV in CFS and cardiomyopathy</td>
</tr>
</tbody>
</table>
HHV-6 & CFS

Jose G. Montoya, MD, Stanford University, USA

Dr. Montoya is Associate Professor of Medicine and Associate Chief for Clinical Affairs for the Division of Infectious Diseases at Stanford University School of Medicine, Director of the Toxoplasmosis Serology Laboratory and Director of the Immunocompromised Host Service at Stanford Medical Center. He is new to the CFS field, but made news recently with his Roche sponsored placebo controlled trial of valganciclovir in a subset of CFS patients with elevated titers to HHV-6 and EBV. Montoya initiated the trial after he found that several CFS patients with exceptionally high antibody titers to HHV-6 & EBV responded very well to antiviral treatment, with full remissions. He hopes to announce the preliminary results of this trial at the conference.

Anthony Komaroff, MD, Harvard Medical School, Boston, USA

Dr. Komaroff is the Simcox-Clifford-Higby professor of medicine at Harvard Medical School (HMS), and editor-in-chief of Harvard Health Publications at HMS. Komaroff was director of the Division of General Medicine at Brigham and Women’s Hospital for 15 years. One of the earliest physician investigators to study Chronic Fatigue Syndrome, Komaroff has been a member of the CFS Coordinating Committee of the U.S. Department of Health and Human Services. One of the first to report HHV-6 reactivation in chronic fatigue syndrome, Dr. Komaroff’s research has found immunological, neuroimaging and neurocognitive deficits in CFS patients that cannot be explained by concurrent depression. His epidemiological research also has helped to establish the point prevalence of CFS in adults living in the U.S.

Kazuhiro Kondo, MD, PhD, Jikei University School of Medicine, Tokyo

Kazuhiro Kondo is Professor and Chairman of the Department of Virology at the Jikei University School of Medicine in Tokyo. He is internationally recognized as one of the top experts on HHV-6 molecular biology. His research focuses on the role of HHV-6 in latency associated genes and the role of HHV-6 & 7 in CFS and other states of fatigue. In a recent study he found that HHV-6 and HHV-7 reactivation in the saliva can be used as objective biomarkers for fatigue. His latest work involves the identification of a novel HHV-6 neurovirulent latent protein that he can cause mood disorders in CFS, psychosis and HHV-6 encephalopathy.

CHRONIC EBV AND CFS

Marshall Williams, PhD, Ohio State University, USA

A specialist in microbiology and immunology, Dr. Williams and his associate Ron Glaser have published ground-breaking research on how stress modulates now the immune system and herpesvirus reactivation, and certain viral enzymes affect normal cellular metabolism and herpesvirus replication. They discovered that the EBV-encoded dUTPase induces the increased expression of pro-inflammatory cytokines and IL-10 from human macrophages and that mice injected with dUTPase develop sickness behavior in the absence of viral replication. They hope to develop drugs based upon the action of the dUTPase which may be useful in cancer and viral chemotherapy.

Brigitte Huber, PhD, Tufts University, Boston, USA

Brigitte Huber studied immunogenetics at University of London and is currently a Professor of Pathology at Tufts University. She is currently studying the presence of retrovirus HERV K-18 as marker for those who might develop CFS after an acute infection such as mononucleosis. Her research shows that EBV induces the HERV K-18 envelope gene to trigger the expression of a specific superantigen and that there are more HERV K-18 alleles in post-mono CFS patients than in controls. She hopes to identify other subsets among CFS patients.

Barbara Savoldo MD, Baylor College of Medicine, Houston, USA

Dr. Savoldo has authored or co-authored over 20 papers on EBV immunotherapy in EBV associated lymphoproliferative disorders and the use of cytotoxic T cell lymphocyte infusion to restore the EBV-specific EBV related T cell responses. She and her associates at Baylor College of Medicine have recently completed a trial of autologous EBV specific CTLs for patients with severe chronic EBV and will report on those findings. Severe chronic EBV was defined in their trial as patients with elevated EBV DNA (over 4,000 copies per ml in the peripheral blood) and free EBV DNA in the serum or spinal fluid. An earlier trial completed in 2002 was successful.
**Symposium Speakers**

**Enterovirus and CFS**

**Nora Chapman, PhD, University of Nebraska, Omaha, USA**

Dr. Chapman studies persistent coxsackievirus infections in murine models of chronic myocarditis and dilated cardiomyopathy. She has demonstrated that the expression of viral proteins in the heart generate significant impairment of cardiomyocyte function and promote the generation of dilated cardiomyopathy. She and her associates at University of Nebraska became interested in the role of enterovirus in CFS after working with Dr. John Chia who found enterovirus infections in the gut biopsies of CFS patients, by staining slides of gut tissues using antigen specific monoclonal antibodies.

**John Chia, MD, UCLA School of Medicine & EV Med Research, California, USA**

Dr. Chia is President of EV Med Research and Assistant Clinical Professor at UCLA School of Medicine. An infectious disease specialist by training, Chia became interested in the role of enterovirus in Chronic Fatigue Syndrome and recently published original research from a study that found 135 out of 165 (82%) of CFS patients had stomach biopsy samples that stained positive for enterovirus antigens compared with 7/34 or 20% of the controls. He also found that 9/24 or 37% of CFS patients had enterovirus RNA in their gut tissue compared to 1 of 21 controls. Dr. Chia is actively investigating treatment strategies for persistent enterovirus infections.

**Parvovirus and CFS**

**Mariko Seishima, MD, Ogaki Municipal Hospital**

Mariko Seishima is a dermatologist who has investigated the underlying cause of various dermatological disorders. Seishima recently studied patients who developed chronic fatigue after a Parvovirus B-19 infection and found that 3 out of 210 developed persistent symptoms. Although Parvovirus DNA and IgM antibodies disappeared from the sera, his group found that complement levels were lower in those who developed CFS than those who did not.

**Dirk Lassner, PhD, of the Charité - Universitätsmedizin Berlin**

A pathologist, Lassner will describe his group’s fascinating finding that in over 1600 endomyocardial biopsies, the most common virus found was parvovirus B-19, followed by HHV-6. All of these cardiomyopathy patients have persistent fatigue. He raises the question: could a subset of CFS patients in fact have subclinical viral myocarditis?

**Borna Virus and CFS**

**Liv Bode, PhD, Robert Koch Institute, Berlin, Germany**

Dr. Bode, PhD, permanent scientist at the Robert Koch Institute and lecturer in virology and infectious diseases at the Free University of Berlin, has authored or co-authored over 45 papers on Borna virus (BDV) infection in both animals and in human psychiatric disease including chronic fatigue. She contributed to high-ranking priority publications on BDV target cells in blood, isolation of human virus, and antiviral therapy (amantadine), the latter shown to be effective both in vitro against human and equine isolates, and in vivo in depressed patients in open trials. Borna virus does not circulate in the blood. Therefore, she and her associates developed sensitive methods to detect the virus activity through circulating immune complexes, antigenemia and free antibodies. Since the diagnosis of Borna virus in humans is controversial, the findings in human disease have been a matter of scientific and even political debate, recently leading to Dr. Bode’s Whistleblower award from the Association of German Scientists (VDW).

Studies in Japan and more recently, in China have demonstrated higher levels of antibodies in patients with CFS than in controls, supporting the suggestion by Bode and her associates that Borna virus plays a role in human neurological disease.

**Keizo Tomonaga, DVM, PhD, Osaka University, Japan**

Dr. Tomonaga has published over 30 papers on Borna virus (BDV). Once thought to be exclusively an animal virus important to horses, this neurotropic virus has now been implicated in human psychiatric disease and chronic fatigue syndrome. Dr. Tomonaga has studied the mechanisms by which Borna virus persists in the brain. He and his associate Kazuyoshi Ikuta have found Borna virus antibodies and Borna virus RNA in the families of CFS patients at higher levels than in controls. Tomonaga has also demonstrated that BDV infection impairs astrocyte function which results in reduced inflammatory response and persistent infection.
**IMMUNOLOGICAL MARKERS AND INFECTION IN CFS**

Nancy Klimas, MD, University of Miami, USA

Dr. Klimas is the President of the International Association for Chronic Fatigue Syndrome/ME, the organization of researchers and clinicians dedicated to furthering our knowledge of this disabling illness. She is a Professor of Medicine, Psychology, Microbiology and Immunology at the University of Miami School of Medicine. Dr Klimas directs the UM/VAMC Gulf War and Chronic Fatigue Syndrome Research Center. Her interests include studying the interaction between inflammation, immune function and the neuroendocrine system in CFS and GWI and has found a number of immune function abnormalities including a defect in NK cell activity. She has also identified a subgroup of CFS patients characterized by impaired natural immunity and cognitive dysfunction. She also studies gene expression before, during and after an exercise challenge in GWI and CFS.

**POST-VIRAL FATIGUE: PROSPECTIVE STUDIES**

Peter White, MD, Queen Mary School of Medicine, London, UK

Peter White is a Professor of Psychological Medicine at the Wolfson Institute of Preventive Medicine. He was an early leader in efforts to learn more about post-viral fatigue and the reason why some patients with acute mononucleosis develop chronic fatigue syndrome, while others are unaffected.

Andrew Lloyd, MD, UNSW School of Medical Sciences

Dr. Lloyd is Associate Professor of the Inflammation Research Unit at the University of New South Wales in Australia. An infectious disease specialist and immunologist, he put together an important CDC-funded prospective study of several hundred patients who developed acute illnesses such as mononucleosis and then followed them over time to determine the percentage that went on to develop Chronic Fatigue Syndrome. He found that roughly 11% of patients who suffer from acute infections of mononucleosis, Q Fever and Ross River fever ultimately go on to develop CFS or post viral fatigue. He has since used these samples to determine that eight key cytokines were not significantly different in the CFS patients compared to those who recovered. He has also gleaned valuable information from this study on the genes that are differentially expressed in post viral fatigue.

Ute Vollmer-Conna, PhD, UNSW School of Psychiatry

Dr. Vollmer-Conna is a psychoneuroimmunologist who has authored or co-authored over a dozen studies on the pathophysiology of post-infective and chronic fatigue. She works with Andrew Lloyd and a multidisciplinary team of scientists and clinicians on the Dubbo Infective Outcomes Study. Her most recent paper reported a comprehensive analysis of the longitudinal production profiles of eight cytokines, which failed to reveal substantive differences between controls and patients with post-viral fatigue.

**MICROARRAY STUDIES**

Jonathan Kerr, MD, PhD, St. George’s University of London, UK

A senior lecturer in inflammation & microbiology, Dr. Kerr also runs a CFS research program funded by two CFS charities in the UK. His interest in CFS began during a study of the parvovirus B-19 infection when he realized that a percentage of cases developed CFS and persisted for several years. His interest in Chronic Fatigue Syndrome (CFS) began during a study of the consequences of parvovirus B19 infection, when he showed that a percentage of infected cases developed CFS which persisted for several years. He has recently reported 88 human genes whose dysregulation is associated with CFS, and which can be used to derive genomic CFS subtypes which have marked differences in clinical phenotype and severity.

Suzanne Vernon, PhD, CFIDS Association of America, USA

Suzanne D. Vernon, Ph.D. joined the staff of the CFIDS Association as Scientific Director in November 2007. Dr. Vernon began her scientific career in 1990 at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia where since 1997 she led the CDCs CFS laboratory team. More than half of her 75 peer-reviewed scientific publications deal with CFS genomics and pathophysiology. In her new capacity as Scientific Director, Dr. Vernon leads the Association's expanded research program which includes developing priorities to achieve expedited progress for therapeutic interventions and cure, building collaborative networks worldwide, and serving as the Association's scientific expert in numerous settings.
NEW TWIN STUDY ON VIRUSES IN CFS

Birgitta Evengård, MD, PhD, Umeå University, Umeå, Sweden

Dr. Evengård is head of the Department of Infectious Disease at Umeå University in Sweden. She previous position was adjunct professor at the Dept Clinical Microbiology at the Karolinska Institute in Stockholm, Sweden. She has published several important studies on fatigue in the context of pathogens. A specialist in infectious diseases and clinical immunology, Dr. Evengård has studied the epidemiology of fatigue in a large study of over 12,000 Swedish twin pairs and found an incidence which was higher than expected and that both environmental and genetic factors were important in chronic fatigue syndrome. In a recent study she found increased levels of Candida albicans in the fecal microflora of chronic fatigue syndrome patients during the acute phase of their illness. Dr. Evengård will include new data on a study of viral markers and cytokines in Swedish twin pairs discordant for CFS in her talk.

KLINICIANS FORUM: TREATING CFS PATIENTS WITH ANTIVIRALS PANEL DISCUSSION

Dan Peterson, MD, Sierra Nevada Internal Medicine, Incline Village, USA

Dr. Peterson is a clinician and CFS expert who documented a CFS outbreak in Nevada in 1985 and who was, along with his partner Paul Cheney, among the first to suggest that viruses such as HHV-6 and EBV might be involved in the Chronic Fatigue Syndrome and co-authored several important papers describing the neurological dysfunction and NK cell deficits found in cases that broke out in Nevada in the late 1980's. Peterson was one of the first to conduct a trial of an antiviral/immunomodulator drug, (Ampligen) for CFS patients. He is also the Medical Director of the Whittemore Peterson Institute for Neuroimmune Disease in Reno, Nevada.

Kenny De Meirleir, MD, PhD, Himmunitas Foundation, Belgium

A prominent clinician/researcher in CFS/ME, Kenny runs a large clinic for CFS/ME patients in Brussels, Belgium. He is also professor of Physiology, Pathophysiology and Medicine at the Vrije Universiteit Brussel and clinical professor at the University of Nevada Medical School in Reno. Kenny has published award winning studies on exercise physiology in CFS.

Kenny has published many research papers on chronic fatigue syndrome issues on topics such as intracellular immune dysfunction, mitochondrial disorders, joint hypermobility, and impairment of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome patients. He has also been a leader in the use of antiviral and immunomodulating treatments such as Ampligen, Kutapressin (Nexavir) and herb/vitamin combinations known to have antiviral/immune boosting qualities.

Martin Lerner, MD, William Beaumont Hospital, Michigan, USA

The former Director of Infectious Diseases at Wayne State University School of Medicine, Dr. Lerner has published over 10 papers since 1993 on the role of subclinical myocarditis in a subset of CFS patients. He has also reported success with long courses of antiviral therapy in patients with chronic EBV and CMV infections. Dr. Lerner uses antibody tests for early antigen to CMV and EBV that are not available in most commercial laboratories; he believes that they are better for differentiating active from latent infections. Although these papers received very little attention in the past, there has been interest in the tie between viral myocarditis and CFS recently since a series of three papers from Germany have found HHV-6 and parvovirus B-19 to be the most common viruses found in biopsies of patients with viral myocarditis. Both viruses are also implicated in CFS.
ABOUT SYMPOSIUM ON VIRUSES IN CHRONIC FATIGUE SYNDROME

WHO SHOULD ATTEND
We encourage research scientists and clinicians, health care workers and providers interested in Chronic Fatigue Syndrome to attend.

MAIN CONFERENCE
The symposium is a satellite conference held just after the 6th International Conference on HHV-6 & 7 to be held June 19-22nd.

SATELLITE CONFERENCE SCHEDULE
The Satellite Conference will begin with lunch at 12:30pm on June 22nd, immediately following the main conference. The first session begins at 2:00pm. The last session on June 23rd ends at 3:30pm and there will be informal discussions until 5:00pm.

REGISTRATION INFORMATION
We prefer online registration at www.hhv-6conference.com/satellite. Forms are provided in this packet if you would like to fax or mail your registration. Registration fees for the satellite conference attendees include the Program and Conference Book and lunch on Monday, June 23rd. Note that if you are attending the Viruses In CFS satellite conference only (and are NOT registering for the HHV-6 & 7 conference), you may attend the June 22nd HHV-6 & 7 Conference session on HHV-6 and neurological disease.

SATELLITE CONFERENCE FEES
Satellite Conference on Viruses in CFS, June 22 - 23 (includes dinner Sunday and lunch Sunday and Monday)

For those attending the main conference, the incremental cost is: $125

For those attending the Viruses in CFS conference only:
• Non-profit rate: $220
• Standard/Corporate Rate: $285

CONFERENCE FEE CANCELLATION POLICY
We will grant a 100% refund up until May 20th. A 50% penalty is charged for cancellation within 30 days and no refund will be granted for cancellation made within seven days of the conference. Cancellations must be written and can be received by either fax, 1-805-565-8731 or email, gwyneth_ramirez@HHV-6foundation.org. It is acceptable to substitute another individual. The Foundation must guarantee meeting space and catering minimum.

HOTEL RATES:
The discounted conference hotel room price is $189 for standard/double occupancy. Students: Note that up to four people can stay per room for the same price. To reserve a hotel room, you may either call the Baltimore Hyatt or register on the hotel website, www.baltimore.hyatt.com. Please use code G-HHV6.

HYATT HOTEL CANCELLATION POLICY
The Hyatt is able to offer a reduced rate only because the Foundation guaranteed a minimum room block. Therefore, the Hyatt is not able to offer a complete refund on hotel reservations. Before May 20th, you may cancel your room with no charge. After May 20th, two nights will be charged and this amount will not be refundable. After June 6th, no refunds will be made. Although we negotiated a room block, we are only intermediaries and requests for refunds for rooms booked must be directed to the hotel.
SATELLITE CONFERENCE
International Symposium on VIRUSES IN CHRONIC FATIGUE SYNDROME & POST-VIRAL FATIGUE
JUNE 22 & 23, 2008

Register by May 20th to receive the hotel room rate guarantee!
Please complete this form and fax, email or mail back to the Foundation.
Fax: 1-805-565-8731  email: gwyneth_ramirez@HHV-6foundation.org
Or mail to: Gwyneth Ramirez, HHV-6 Foundation, 277 San Ysidro Road, Santa Barbara, CA 93108, USA

CONTACT INFORMATION:

<table>
<thead>
<tr>
<th>Salutation: Dr. Mr. Mrs. Ms.</th>
<th>First Name</th>
<th>Last Name</th>
<th>Nickname (for badge)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree</td>
<td>Title/Position</td>
<td>Department</td>
<td>Institution</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Street Address</th>
<th>City</th>
<th>State/Province</th>
<th>Zip/Postal Code</th>
<th>Country</th>
</tr>
</thead>
</table>

Email Address       Phone (office)    Phone (mobile)

CONFERENCE RATES (includes a special dinner Sunday night and lunch Monday):
Non-Profit/Academic Rate: **$220**      Corporate/Regular Rate: **$285**
Price for those attending main conference on HHV-6 & 7 (June 19-22): **$125**

HOTEL ACCOMODATIONS:
Please contact the Hyatt Regency Hotel directly to reserve a room for your conference attendance. A guaranteed rate of $189 is available to conference attendees if the reservation is made before May 20th. After May 20th the standard hotel rates will apply. The conference code is G-HHV6.
The Hyatt Regency Baltimore, 300 Light Street, Baltimore, MD 21202
Website: www.baltimore.hyatt.com   Phone: +1 410 528 1234

OPTIONAL: ACCOMPANYING PERSON
Please note that dinner Sunday night and lunch on Sunday and Monday are available to accompanying persons for an additional cost of $100 per person.

Name of accompanying person(s)

Total conference fees: $

☐ Check enclosed. Make check payable to the HHV-6 Foundation International Conference in US dollars. Please include registrant’s name on the check and return this form with payment. If you need to send a check in a foreign currency, please add a fee of $25 US to cover processing fees.

☐ Please charge my credit card.  ☐ Visa      ☐ MasterCard      ☐ American Express

Name as it appears on credit card     Signature     Billing address

Credit Card Number     Expiration date
International Symposium on VIRUSES IN CHRONIC FATIGUE SYNDROME & POST-VIRAL FATIGUE

June 22 & 23, 2008
Baltimore, Maryland, USA

A satellite meeting of the 6th International Conference on HHV-6 & 7